<DOC>
	<DOCNO>NCT00008021</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill cancer cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy , cyclosporine , paclitaxel follow peripheral stem cell transplantation treat patient refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy , Chemotherapy , Peripheral Stem Cell Transplantation Treating Patients With Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 monoclonal antibody Lym-1 administer cyclosporine paclitaxel follow autologous peripheral blood stem cell transplantation patient refractory non-Hodgkin 's lymphoma . - Determine toxicity treatment regimen patient . OUTLINE : This open-label , dose escalation study yttrium Y 90 monoclonal antibody Lym-1 ( Y90 MOAB Lym-1 ) . Patients assign one four cohort . - Cohort I : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin 4 day prior peripheral blood stem cell ( PBSC ) mobilization continue adequate PBSC collect . Patients receive unlabeled monoclonal antibody ( MOAB ) Lym-1 IV follow tracer dose indium In 111 MOAB Lym-1 ( In111 MOAB Lym-1 ) IV day 0 unlabeled MOAB Lym-1 IV follow Y90 MOAB Lym-1 IV day 7 . Patients also receive oral cyclosporine every 12 hour day -2 14 . Patients may undergo autologous PBSC transplantation , necessary , early day 17 receive G-CSF SC begin completion PBSC re-infusion continue blood count recover . - Cohort II : Patients undergo PBSC mobilization receive treatment cohort I . Patients also receive paclitaxel IV 3 hour day 9 . - Cohort III : Patients undergo PBSC mobilization receive unlabeled MOAB Lym-1 , In111 MOAB Lym-1 , Y90 MOAB Lym-1 , cyclosporine cohort I paclitaxel cohort II . Patients undergo autologous PBSC transplantation earlier day 17 . Patients receive G-CSF transplantation cohort I . - Cohort IV : Patients undergo PBSC mobilization receive treatment cohort III . Treatment repeat every 6 week 2 course absence disease progression unacceptable toxicity . Cohorts 1 3 patient receive escalate dos Y90 MOAB Lym-1 maximum tolerate dose ( MTD ) determine . The MTD define dose 1 3 patient require PBSC transplantation , dose precede 2 3 patient experience dose-limiting toxicity . Patients follow monthly 3 month , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A maximum 40 patient accrue study within 36 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma ( NHL ) fail standard therapy Any grade allow Intermediate high grade NHL must fail standard therapy curative intent Measurable disease HAMA titer negative NHL tissue Lym1 reactive vitro Bilateral bone marrow biopsy le 25 % NHL No evidence myelodysplastic syndrome bone marrow NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 130,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST great 84 U/L Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : LVEF least 50 % Pulmonary : FEV1 least 60 % predict FVC least 60 % predict Corrected DLCO least 50 % Other : No malignancy within past 5 year except non melanoma skin cancer HIV negative No AIDS Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy involve 25 % bone marrow At least 4 week since prior external beam radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>